Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Janux Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Janux Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Campbell David Alan | President and CEO | 264,742 | Jul 31, 2026 | 3 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 11,750Indirect | Jun 12, 2026 | 1 |
| Ra Capital Management, L.P. | Director, 10% Owner | 11,750Indirect | Jun 12, 2026 | 1 |
| Kolchinsky Peter | Director, 10% Owner | 11,750Indirect | Jun 12, 2026 | 1 |
| Shah Rajeev M. | Director, 10% Owner | 11,750Indirect | Jun 12, 2026 | 1 |
| RA Capital Nexus Fund II, L.P. | Director | 11,750Indirect | Jun 12, 2026 | 1 |
| Dobmeier Eric | Director | 15,481 | Jun 12, 2026 | 1 |
| Capps Vickie L | Director | 79,598 | Jun 12, 2026 | 1 |
| Barrett Ronald W | Director | 11,750 | Jun 12, 2026 | 1 |
| Kung Winston | Director | 11,750 | Jun 12, 2026 | 1 |
| Hernday Natasha | Director | 15,481 | Jun 12, 2026 | 1 |
| Simson Jake | Director | 11,750 | Jun 12, 2026 | 1 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | 75,941 | Jun 4, 2026 | 2 |
| Dobek Maria | Vice President, Accounting | 32,270 | May 13, 2026 | 2 |
| Go William | Chief Medical Officer | 44,000 | Feb 4, 2026 | 1 |
| Meyer Andrew Hollman | Chief Business Officer | 83,095 | Jan 2, 2026 | 4 |
| Winter Charles M. | Chief Technical Officer | 106,321 | Jan 2, 2026 | 1 |
| DiRaimondo Thomas | Chief Scientific Officer | 155,825 | Jan 2, 2026 | 1 |
| McIver Zachariah | Chief Medical Officer | 52,286 | Jan 2, 2026 | 1 |
| Gujrathi Sheila | Director | 118,889 | Jun 13, 2025 | 0 |
| McNulty Alana B. | Director | 6,250 | Jun 13, 2025 | 0 |
| Robinson Byron | Chief Strategy Officer | 28,000 | Jan 3, 2025 | 0 |
| Lichter Jay | 10% Owner | 7,000 | Oct 24, 2024 | 0 |
| Avalon Ventures XI, L.P. | 10% Owner | 2,115,373Indirect | Oct 18, 2024 | 0 |
| Avalon BioVentures SPV I, L.P. | 10% Owner | 2,115,373Indirect | Oct 18, 2024 | 0 |
| Avalon BioVentures I, LP | 10% Owner | 2,115,373Indirect | Oct 18, 2024 | 0 |
| Reardon Tighe | Acting Chief Financial Officer | 3,340,018Indirect | Jun 5, 2024 | 0 |
| Godfrey Wayne | Chief Medical Officer | – | Jan 5, 2023 | 0 |
| Thompson Peter A. | Director | 231,098Indirect | Jun 16, 2022 | 0 |
| Heller Stefan | Director | – | Jun 16, 2022 | 0 |
| Salek-Ardakani Shahram | Chief Scientific Officer | – | Jan 5, 2022 | 0 |
| OrbiMed Advisors LLC | Director | 231,098Indirect | Dec 30, 2021 | 0 |
| OrbiMed Genesis GP LLC | Director | 231,098Indirect | Dec 30, 2021 | 0 |
| OrbiMed Capital GP VIII LLC | Director | 231,098Indirect | Dec 30, 2021 | 0 |
| OrbiMed Capital GP VII LLC | Director | 245,898Indirect | Dec 17, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 (view filing) | Jun 2 | 2 days | Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | SSale | −4.06K | $14.03 | −$56.9K | −5.1%75.9K after |